Transfusion of red blood cell
Conditions
Interventions
Group 1:Transfusion of ubiquitin-removed stored red blood cell
Group 2:Transfusion of not ubiquitin-removed stored red blood cell
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years; 2. Adult patients undergoing total hip replacement who experiences excessive bleeding during intraoperative period and receive red blood cell transfusion, or hemoglobin<8g/dl, or patients who has anemia during perioperative period; 3. Adult patients undergoing cardiac surgery who experiences excessive bleeding during intraoperative period and receive red blood cell transfusion, or hemoglobin<7.5g/dl, or patients who has anemia during perioperative period; 4. Adult patients undergoing liver transplantation surgery who experiences excessive bleeding during intraoperative period and receive red blood cell transfusion, or hemoglobin<8g/dl, or patients who has anemia during perioperative period; 5. Adult patients undergoing acute gastrointestinal bleeding and receive red blood cell transfusion, or hemoglobin<7g/dl, or according to the patients cardiopulmonary, metabolism, oxygen consumption and hemodynamic conditions; 6. Adult patients undergoing tumor resection surgery who experiences excessive bleeding during intraoperative period and receive red blood cell transfusion, or hemoglobin<7g/dl, or patients who has anemia during perioperative period 7. Adult patients who has hematological malignanciessuch as: lymphoma, leukemia, myelodysplastic syndromesaplastic anemiahemoglobin<7g/dl, or according to the patients cardiopulmonary, metabolism, oxygen consumption and hemodynamic conditions; 8. Patients with complete clinical examination, laboratory examination, medical record and medical history.
Exclusion criteria
Exclusion criteria: 1. Psychiatric disorders; 2. Patients who dont have complete clinical data; 3. Patients who undergoing surgery or gastrointestinal bleeding, hematological malignancies should be excluded, and no immunomodulatory drugs be used during transfusion and examination; 4. Patients who have hematological malignancies should be in their intermission of chemotherapy, and no immunomodulatory drugs be used during transfusion and examination.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse Event after transfusion;immunocyte function; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospital stay; | — |
Countries
China
Contacts
Public ContactRong Xia
Department of Blood Transfusion, Huashan Hospital, Fudan University
Outcome results
None listed